Zobrazeno 1 - 10
of 818
pro vyhledávání: '"J E, Foley"'
Publikováno v:
The British Medical Journal, 1969 Jul . 3(5663), 183-183.
Externí odkaz:
https://www.jstor.org/stable/20377118
Publikováno v:
Irish Journal of Psychological Medicine. 36:145-151
AimTo investigate whether a small regional memory clinic would benefit from engaging with a structured external audit process such as the Royal College of Psychiatrists’ Memory Service National Accreditation Program (MSNAP).BackgroundThe Psychiatry
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61f215c050bec78ac39da7975b6085dd
https://doi.org/10.1017/ipm.2018.14
https://doi.org/10.1017/ipm.2018.14
Autor:
Eva Ekblad, Bilal Omar, Bo Ahrén, Ulrikke Voss, J E Foley, Maria Sörhede Winzell, Jenny Vikman
Publikováno v:
Diabetologia. 56:1752-1760
Studies have shown that dipeptidyl peptidase-4 (DPP4) inhibitors stimulate insulin secretion and increase beta cell mass in rodents. However, in these models hyperglycaemia has been induced early on in life and the treatment periods have been short.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b1c726148049e88a1601662ea9ca644
https://doi.org/10.1007/s00125-013-2927-8
https://doi.org/10.1007/s00125-013-2927-8
Publikováno v:
Diabetic Medicine. 25:435-441
Aims To compare the efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor, vildagliptin, with the alpha glucosidase inhibitor, acarbose, in drug-naive patients with Type 2 diabetes. Methods This multi-centre, randomized, double-blind, par
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15c85210bd0fc289b59721ddc3204328
https://doi.org/10.1111/j.1464-5491.2008.02391.x
https://doi.org/10.1111/j.1464-5491.2008.02391.x
Publikováno v:
International Journal of Clinical Practice. 62:8-14
Vildagliptin is a potent, selective and reversible inhibitor of dipeptidyl peptidase-4 (DPP-4), the enzyme responsible for rapid inactivation of the incretin hormones glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP). GLP-1 and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::437b4a4784687639e21ea4525acd2c34
https://doi.org/10.1111/j.1742-1241.2007.01685.x
https://doi.org/10.1111/j.1742-1241.2007.01685.x
Publikováno v:
Hormone and metabolic research 39 (2007): 826–829.
info:cnr-pdr/source/autori:Ahren B, Pacini G, Tura A, Foley JE and Schweizer A,/titolo:Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes/doi:/rivista:Hormone and metabolic research/anno:2007/pagina_da:826/pagina_a:829/intervallo_pagine:826–829/volume:39
info:cnr-pdr/source/autori:Ahren B, Pacini G, Tura A, Foley JE and Schweizer A,/titolo:Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes/doi:/rivista:Hormone and metabolic research/anno:2007/pagina_da:826/pagina_a:829/intervallo_pagine:826–829/volume:39
The aim of this study was to evaluate the contribution of insulin processing to the improved meal-related B-cell function previously shown with the DPP-4 inhibitor vildagliptin. Fifty-five patients with type 2 diabetes (56.5+/-1.5 years; BMI=29.6+/-0
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e8d600ddc442afa8da37fc6ef3d11f6
https://doi.org/10.1055/s-2007-991172
https://doi.org/10.1055/s-2007-991172
Publikováno v:
Diabetologia. 48:1700-1713
Although there is abundant evidence that hyperglucagonaemia plays a key role in the development of hyperglycaemia in type 2 diabetes, efforts to understand and correct this abnormality have been overshadowed by the emphasis on insulin secretion and a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49359ecb9f28321711fa2db0df430cf3
https://doi.org/10.1007/s00125-005-1878-0
https://doi.org/10.1007/s00125-005-1878-0
Autor:
Davidson A; Vaccines and Antivirals Medical Affairs, Pfizer Inc., New York, New York, USA., Kelly PH; Vaccines and Antivirals Medical Affairs, Pfizer Inc., New York, New York, USA., Davis J; Life Sciences, Clarivate Analytics, Chandler, Arizona, USA., Major M; Vaccines Medical Affairs, Pfizer Canada ULC, Kirkland, Quebec, Canada., Moïsi JC; Vaccines and Antivirals Medical Affairs, Pfizer Inc., Paris, France., Stark JH; Vaccines and Antivirals Medical Affairs, Pfizer Inc., Cambridge, Massachusetts, USA.
Publikováno v:
Zoonoses and public health [Zoonoses Public Health] 2024 Nov 22. Date of Electronic Publication: 2024 Nov 22.
Publikováno v:
Diabetes, obesitymetabolism. 16(9)
To determine the effects of dipeptidyl peptidase-4 (DPP-4) inhibition on glucagon dynamics in patients with insulin-treated type 2 diabetes (T2D).The study was a single-centre, double-blind, randomized, placebo controlled crossover study in patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afa0e9a54f187b02d744b7c576d8a8ce
https://pubmed.ncbi.nlm.nih.gov/24612221
https://pubmed.ncbi.nlm.nih.gov/24612221
Publikováno v:
Bulgarian Journal of Veterinary Medicine. Sep2024, Vol. 27 Issue 3, p375-386. 12p.